Glass Pharms Release Their Own Brand Cannabis Flower Range To The Uk Market.

July 31, 2024 08:03 AM BST | By Pressat
 Glass Pharms Release Their Own Brand Cannabis Flower Range To The Uk Market.
Image source: Pressat
Wednesday 31 July, 2024

Glass Pharms, the UK-based medical cannabis cultivation company based at a purpose-built 2.4-hectare facility in Wiltshire, have launched their own-branded range of Cannabis-based products for medicinal use (CBPMs) with a UK pharmaceutical manufacturing partner, which will be available at several pharmacies.

Using cannabis flower grown at the facility, the medicines will offer a range of prescribing options to UK clinicians and patients that have previously been inconsistently available. The initial launch will include a High-CBD flower that contains less than 1% THC, a ratio which according to a recent published study by the University of Colorado Boulder, may be more effective in treating anxiety than other flowers with higher THC content.1

“As well as producing High-THC Cannabis flower, we have a commitment to bring CBD-containing medical cannabis flower to the UK market as we believe it gives prescribers options for cannabis-naive patients that would otherwise be missing.” said James Duckenfield, Glass Pharms’ CEO “Careful titration of THC content has been shown to improve the initial patient experience and led to better outcomes for new users of medical cannabis.”

Other flowers that will be available immediately include an entry-level High-THC flower and a high terpene content High-THC flower. More cultivars will become available in the Glass Pharms-branded range over the next few months.

The CBPMs will be manufactured to the new British Pharmacopeia (BP) standard for Cannabis flower which became legally binding in the UK on July 1st of this year, returning Cannabis flower as a medicine to the British Pharmacopeia after it was removed for prohibitionist reasons in 1932, after having been included since the first edition published in 1864.

The flower is non-irradiated and produced to exacting microbial standards in the purpose-built facility, which was specifically designed to produce Cannabis flower to pharmaceutical standards.

Glass Pharms’ ultra-modern facility operates off-grid, powered by food waste that is turned into energy in an adjacent anaerobic digestion plant, giving the cannabis flower grown at the facility a best-in-class sustainability profile.

For more information contact: Mark Heley, External Relations, Glass Pharms

[email protected]
07904 856199

1https://cannabishealthnews.co.uk/2024/03/06/study-finds-cbd-can-ease-anxiety-more-effectively-than-thc/

Acute and Extended Anxiolytic Effects of Cannabidiol in Cannabis Flower: A Quasi-Experimental ad libitum Use Study

https://www.liebertpub.com/doi/10.1089/can.2023.0187


Distributed by https://pressat.co.uk/


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalized advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


Sponsored Articles


Investing Ideas

Previous Next